Renal Denervation Market by Product (Symplicity, EnligHTN, Vessix, Paradise and Iberis) and by Technology (Radiofrequency, Ultrasound and Micro-Infusion) - Global Opportunity Analysis and Industry Forecast, 2014-2022

September 2016 | 110 pages | ID: R5B6D44A292EN
Allied Market Research

Abstracts

Renal denervation is a minimally invasive catheter-based procedure for the treatment of hypertension in patients. It is generally opted in cases where medicines fail to provide relief to the patient. In this procedure, nerves of the renal artery wall are ablated with the help of radiofrequency pulses or ultrasound. This leads to a reduction of sympathetic afferent and efferent kidney activity, which further leads to a reduction in blood pressure.
The world renal denervation market was $197 million in 2015 and is expected to reach $3,153 million by 2022 with a CAGR of 48.5%. The market is driven by factors such as changes in lifestyle of the people, which leads to uncontrolled, treatment resistant hypertension, and ageing population. In addition to this, technological advancements have helped in the development of innovative and efficient denervation devices that have driven the market growth. However, low awareness for renal denervation procedure, stringent regulatory norms for renal denervation systems, and unfavorable reimbursements for renal denervation procedure have restricted the growth of the market.

The report segments the market based on product, technology, and geography. Based on product, it is segmented into Symplicity Renal Denervation System, EnligHTN, Vessix Renal Denervation System, Paradise Renal Denervation System, and Iberis Renal Sympathetic Denervation System. Based on technology, the market is segmented into radiofrequency, ultrasound, and micro-infusion. Based on geography, the market is divided into four major regions, namely, North America (the U.S., Canada, and Mexico), Europe (Germany, France, U.K., Italy, and Spain), Asia-Pacific (Japan, China, India, Australia, and New Zealand), and LAMEA (Brazil, South Africa, and Saudi Arabia).
The market has witnessed product development and acquisitions in the recent years. These acquisitions have helped the major players to combine their forces with smaller players and enhance their business. In this regard, Boston Scientific Corporation acquired Vessix Vascular, Inc. (November 2012) and Medtonic plc acquired Ardian, Inc. (January 2011). Both Vessix Vascular, Inc. and Ardian, Inc. were the producers of renal denervation devices. However, due to smaller production capacities and limited geographical presence the systems were not popular in the market. However, after the acquisition these systems were produced on a large scale. This enabled Medtonic plc and Boston Scientific Corporation to emerge as the top leading companies for renal denervation devices.
Key players that operate in this market include Ablative Solutions, Inc., Boston Scientific Corporation, Cardiosonic Ltd, Kona Medical, Inc., Medtronic plc, Mercator MedSystems, Inc., ReCor Medical, Inc., Renal Dynamics Limited, St. Jude Medical, Inc., and Terumo Medical Corporation.

KEY BENEFITS FOR STAKEHOLDERS:

• The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
• The report provides a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Extensive analysis by products interprets various types of devices used for renal denervation.
• Competitive intelligence highlights the business practices followed by leading players across different regions.
• Comprehensive analysis of all geographic regions are provided to determine the prevailing opportunities in these geographies.
• Key market players are profiled in the report and their strategies are analyzed thoroughly, which predict the competitive outlook of the global market.
• Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

KEY MARKET SEGMENTS:

By Product

• Symplicity Renal Denervation System
• EnligHTN
• Vessix Renal Denervation System
• Paradise Renal Denervation System
• Iberis Renal Sympathetic Denervation System
• Others

By Technology

• Radiofrequency
• Ultrasound
• Micro-infusion

By Geography

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• New Zealand
• Rest of Asia-Pacific
• LAMEA
• Brazil
• South Africa
• Saudi Arabia
• Rest of LAMEA

Contents

CHAPTER 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
  1.4.1 Secondary research
  1.4.2 Primary research
  1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Key findings
  3.2.1 Top investment pockets
  3.2.2 Top winning strategies
    3.2.2.1 Competitive intelligence of companies and their strategies
3.3 Porters five forces analysis
  3.3.1 Bargaining power of the suppliers
  3.3.2 Bargaining power of buyers
  3.3.3 Threat of new entrants
  3.3.4 Competitive rivalry
  3.3.5 Threat of substitutes
3.4 Market share analysis, 2015
3.5 Market dynamics
  3.5.1 Drivers
    3.5.1.1 Prevalence of hypertension
    3.5.1.2 Changing lifestyle of people
    3.5.1.3 Improvement of healthcare infrastructure in developing countries
    3.5.1.4 Cost effectiveness of the procedure
  3.5.2 Restraints
    3.5.2.1 Painful procedure
    3.5.2.2 Stringent approval process for renal denervation devices
  3.5.3 Opportunities
    3.5.3.1 Applications of renal denervation in other diseases
    3.5.3.2 Clinical Trials
3.6 Clinical trials
  3.6.1 The Symplicity clinical trial program
    3.6.1.1 SYMPLICITY HTN-1
    3.6.1.2 SYMPLICITY HTN-2
    3.6.1.3 SYMPLICITY HTN-3
    3.6.1.4 Global SYMPLICITY Registry
    3.6.1.5 SYMPLICITY-HF
    3.6.1.6 Symplicity Spyral(TM) Catheter Feasibility Study
    3.6.1.7 HTN-Japan
    3.6.1.8 SYMPLICITY HTN-India
  3.6.2 Clinical trials for EnligHTN renal denervation system
    3.6.2.1 EnligHTN I Trial
    3.6.2.2 EnligHTN II Trial
    3.6.2.3 EnligHTN III Trial
    3.6.2.4 EnligHTN IV Trial
    3.6.2.5 EnligHTNment Trial
  3.6.3 Other clinical trials

CHAPTER 4 WORLD RENAL DENERVATION MARKET, BY PRODUCT

4.1 Overview
  4.1.1 Market size and forecast
4.2 Symplicity
  4.2.1 Key market trends
  4.2.2 Key growth factors and opportunities
  4.2.3 Market size and forecast
4.3 Vessix (V2)
  4.3.1 Key market trends
  4.3.2 Key growth factors and opportunities
  4.3.3 Market size and forecast
4.4 EnligHTN
  4.4.1 Key market trends
  4.4.2 Key growth factors and opportunities
  4.4.3 Market size and forecast
4.5 Paradise
  4.5.1 Key market trends
  4.5.2 Key growth factors and opportunities
  4.5.3 Market size and forecast
4.6 Iberis
  4.6.1 Key market trends
  4.6.2 Key growth factors and opportunities
  4.6.3 Market size and forecast
4.7 Others
  4.7.1 Key market trends
  4.7.2 Key growth factors and opportunities
  4.7.3 Market size and forecast

CHAPTER 5 WORLD RENAL DENERVATION MARKET, BY TECHNOLOGY

5.1 Overview
  5.1.1 Market size and forecast
5.2 Radiofrequency
  5.2.1 Market size and forecast
5.3 Ultrasound
  5.3.1 Market size and forecast
5.4 Micro-infusion
  5.4.1 Market size and forecast

CHAPTER 6 WORLD RENAL DENERVATION MARKET, BY GEOGRAPHY, 2014-2022

6.1 Overview
  6.1.1 Market size and forecast
6.2 North America
  6.2.1 Key market trends
  6.2.2 Key growth factors and opportunities
  6.2.3 Market size and forecast
  6.2.4 U.S. market size and forecast
  6.2.5 Canada market size and forecast
  6.2.6 Mexico market size and forecast
6.3 Europe
  6.3.1 Key market trends
  6.3.2 Key growth factors and opportunities
  6.3.3 Market size and forecast
  6.3.4 Germany market size and forecast
  6.3.5 France market size and forecast
  6.3.6 U.K. market size and forecast
  6.3.7 Italy market size and forecast
  6.3.8 Spain market size and forecast
  6.3.9 Rest of Europe market size and forecast
6.4 Asia-Pacific
  6.4.1 Key market trends
  6.4.2 Key growth factors and opportunities
  6.4.3 Market size and forecast
  6.4.4 Japan market size and forecast
  6.4.5 China market size and forecast
  6.4.6 India market size and forecast
  6.4.7 Australia market size and forecast
  6.4.8 New Zealand market size and forecast
  6.4.9 Others market size and forecast
6.5 LAMEA
  6.5.1 Key market trends
  6.5.2 Key growth factors and opportunities
  6.5.3 Market size and forecast
  6.5.4 Brazil market size and forecast
  6.5.5 South Africa market size and forecast
  6.5.6 Saudi Arabia market size and forecast
  6.5.7 Rest of LAMEA market size and forecast

CHAPTER 7 COMPANY PROFILES

7.1 Ablative Solutions, Inc.
  7.1.1 Company Overview
  7.1.2 Company Snapshot
  7.1.3 Operating Business Segments
  7.1.4 Key Strategic Moves & Developments
7.2 Boston Scientific Corporation
  7.2.1 Company Overview
  7.2.2 Operating Business Segments
  7.2.3 Business Performance
  7.2.4 Key Strategic Moves & Developments
7.3 Cardiosonic Ltd
  7.3.1 Company Overview
  7.3.2 Company Snapshot
  7.3.3 Key Strategic Moves & Developments
7.4 Kona Medical, Inc.
  7.4.1 Company Overview
  7.4.2 Company Snapshot
  7.4.3 Key Strategic Moves & Developments
7.5 Medtronic plc
  7.5.1 Company Overview
  7.5.2 Company Snapshot
  7.5.3 Operating Business Segments
  7.5.4 Business Performance
  7.5.5 Key Strategic Moves & Developments
7.6 Mercator MedSystems, Inc.
  7.6.1 Company Overview
  7.6.2 Company Snapshot
  7.6.3 Operating Business Segments
  7.6.4 Key Strategic Moves & Developments
7.7 ReCor Medical, Inc.
  7.7.1 Company Overview
  7.7.2 Company Snapshot
  7.7.3 Key Strategic Moves & Developments
7.8 Renal Dynamics Limited
  7.8.1 Company Overview
  7.8.2 Company Snapshot
  7.8.3 Key Strategic Moves & Developments
7.9 St. Jude Medical, Inc.
  7.9.1 Company Overview
  7.9.2 Operating Business Segments
  7.9.3 Business Performance
  7.9.4 Key Strategic Moves & Developments
7.10 Terumo Corporation
  7.10.1 Company Overview
  7.10.2 Company Snapshot
  7.10.3 Operating Business Segments
  7.10.4 Business Performance
  7.10.5 Key Strategic Moves & Developments

List Of Tables

LIST OF TABLES

TABLE 1 OTHER CLINICAL TRIALS
TABLE 2 WORLD RENAL DENERVATION MARKET, BY TYPE, 20142022 ($MILLION)
TABLE 3 SYMPLICITY RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 4 VESSIX RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 5 ENLIGHTN RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 6 PARADISE RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 7 IBERIS RENAL DENERVATION SYSTEM MARKET, BY REGION, 20142022 ($MILLION)
TABLE 8 OTHER RENAL DENERVATION SYSTEMS MARKET, BY REGION, 20142022 ($MILLION)
TABLE 9 WORLD RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 10 RADIOFREQUENCY RENAL DENERVATION MARKET, BY REGION, 20142022 ($MILLION)
TABLE 11 ULTRASOUND RENAL DENERVATION MARKET, BY REGION, 20142022 ($MILLION)
TABLE 12 MICRO-INFUSION RENAL DENERVATION MARKET, BY REGION, 20142022 ($MILLION)
TABLE 13 RENAL DENERVATION MARKET, BY GEOGRAPHY, 20142022 ($MILLION)
TABLE 14 NORTH AMERICA: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 15 NORTH AMERICA: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 16 NORTH AMERICA: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 17 EUROPE: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 18 EUROPE: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 19 EUROPE: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 20 ASIA-PACIFIC: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 21 ASIA-PACIFIC: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 22 ASIA-PACIFIC: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 23 LAMEA: RENAL DENERVATION MARKET, BY COUNTRY, 20142022 ($MILLION)
TABLE 24 LAMEA: RENAL DENERVATION MARKET, BY PRODUCT, 20142022 ($MILLION)
TABLE 25 LAMEA: RENAL DENERVATION MARKET, BY TECHNOLOGY, 20142022 ($MILLION)
TABLE 26 ABLATIVE SOLUTIONS: COMPANY SNAPSHOT
TABLE 27 BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 28 BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 29 CARDIOSONIC: COMPANY SNAPSHOT
TABLE 30 KONA MEDICAL: COMPANY SNAPSHOT
TABLE 31 MEDTRONIC: COMPANY SNAPSHOT
TABLE 32 MEDTRONIC: OPERATING SEGMENTS
TABLE 33 MERCATOR: COMPANY SNAPSHOT
TABLE 34 RECOR MEDICAL: COMPANY SNAPSHOT
TABLE 35 RENAL DYNAMICS - COMPANY SNAPSHOT
TABLE 36 ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 37 ST. JUDE MEDICAL: PRODUCT CATEGORIES
TABLE 38 TERUMO: COMPANY SNAPSHOT
TABLE 39 TERUMO: OPERATING SEGMENTS

List Of Figures

LIST OF FIGURES

FIG. 1 WORLD RENAL DENERVATION MARKET, BY PRODUCT, 2015 VS 2022, ($MILLION)
FIG. 2 RENAL DENERVATION MARKET SEGMENTATION
FIG. 3 TOP INVESTMENT POCKETS IN THE WORLD RENAL DENERVATION MARKET
FIG. 4 TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, (20142016)
FIG. 5 TOP WINNING STRATEGIES: NATURE AND TYPE
FIG. 6 TOP COMPANIES AND THEIR STRATEGIES
FIG. 7 DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIG. 8 DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIG. 9 PORTERS FIVE FORCES ANALYSIS
FIG. 10 MARKET SHARE ANALYSIS, 2015
FIG. 11 TOP IMPACTING FACTORS: RENAL DENERVATION MARKET
FIG. 12 MAIN FACTORS THAT CONTRIBUTE TO THE DEVELOPMENT OF HIGH BLOOD PRESSURE AND ITS COMPLICATIONS
FIG. 13 HYPERTENSION CONTROL IN PATIENTS TREATED BY MULTIDRUG APPROACH, (% OF PATIENTS)
FIG. 14 WORLDWIDE HYPERTENSION POPULATION
FIG. 15 MAJOR CLINICAL TRIALS IN RENAL DENERVATION MARKET
FIG. 16 EUROPE CLINICAL TRIALS, (%)
FIG. 17 ASIA-PACIFIC CLINICAL TRIALS, (%)
FIG. 18 NORTH AMERICA CLINICAL TRIALS, (%)
FIG. 19 LAMEA CLINICAL TRIALS, (%)
FIG. 20 PIPELINE PRODUCTS IN RENAL DENERVATION MARKET
FIG. 21 PREVALENCE OF RESISTANT HYPERTENSION IN NORTH AMERICA (%)
FIG. 22 U.S.: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 23 CANADA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 24 MEXICO: COSMETIC IMPLANTS MARKET, 20142022 ($MILLION)
FIG. 25 PREVALENCE OF RESISTANT HYPERTENSION IN EUROPE (%)
FIG. 26 GERMANY: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 27 FRANCE: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 28 UK: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 29 ITALY: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 30 SPAIN: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 31 REST OF EUROPE: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 32 PREVALENCE OF RESISTANT HYPERTENSION IN ASIA-PACIFIC (%)
FIG. 33 JAPAN: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 34 CHINA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 35 INDIA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 36 AUSTRALIA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 37 NEW ZEALAND: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 38 OTHERS ASIA-PACIFIC: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 39 PREVALENCE OF RESISTANT HYPERTENSION IN LAMEA (%)
FIG. 40 BRAZIL: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 41 SOUTH AFRICA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 42 SAUDI ARABIA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 43 REST OF LAMEA: RENAL DENERVATION MARKET, 20142022 ($MILLION)
FIG. 44 BOSTON SCIENTIFIC: NET SALES, 20132015 ($MILLION)
FIG. 45 BOSTON SCIENTIFIC: NET SALES, BY SEGMENT, 2015 (%)
FIG. 46 BOSTON SCIENTIFIC: NET SALES, BY GEOGRAPHY, 2015 (%)
FIG. 47 MEDTRONIC: NET SALES, 20142016 ($MILLION)
FIG. 48 MEDTRONIC: NET SALES, BY SEGMENT, 2016 (%)
FIG. 49 MEDTRONIC: NET SALES, BY GEOGRAPHY, 2016 (%)
FIG. 50 MEDTRONIC: STRATEGY SHARE, 20132014 (%)
FIG. 51 ST. JUDE MEDICAL: NET SALES, 20132015 ($MILLION)
FIG. 52 ST. JUDE MEDICAL: NET SALES, BY PRINCIPLE PRODUCT CATEGORY, 2015 (%)
FIG. 53 ST. JUDE MEDICAL: NET SALES, BY GEOGRAPHY, 2015 (%)
FIG. 54 TERUMO: NET SALES, 20142016 ($MILLION)
FIG. 55 TERUMO: NET SALES, BY SEGMENT, 2016 (%)
FIG. 56 TERUMO: NET SALES, BY GEOGRAPHY, 2016 (%)